213 related articles for article (PubMed ID: 22836805)
1. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.
Hama R; Watanabe Y; Shinada K; Yamada Y; Ogata Y; Yoshida Y; Tamura T; Hiraishi T; Oikawa R; Sakurai J; Maehata T; Koizumi H; Itoh F
Tumour Biol; 2012 Dec; 33(6):2031-40. PubMed ID: 22836805
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
3. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
6. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
7. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
8. A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly.
Musti M; Cavone D; Aalto Y; Scattone A; Serio G; Knuutila S
Cancer Genet Cytogenet; 2002 Oct; 138(1):73-6. PubMed ID: 12419589
[TBL] [Abstract][Full Text] [Related]
9. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
Dragon J; Thompson J; MacPherson M; Shukla A
J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
[TBL] [Abstract][Full Text] [Related]
10. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
11. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.
Destro A; Ceresoli GL; Baryshnikova E; Garassino I; Zucali PA; De Vincenzo F; Bianchi P; Morenghi E; Testori A; Alloisio M; Santoro A; Roncalli M
Lung Cancer; 2008 Mar; 59(3):369-76. PubMed ID: 17920725
[TBL] [Abstract][Full Text] [Related]
12. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
13. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
14. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
Del Gobbo A; Fiori S; Gaudioso G; Bonaparte E; Tabano S; Palleschi A; Bosari S; Ferrero S
Int J Clin Exp Pathol; 2014; 7(5):2484-9. PubMed ID: 24966960
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
16. A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
Desmeules P; Joubert P; Zhang L; Al-Ahmadie HA; Fletcher CD; Vakiani E; Delair DF; Rekhtman N; Ladanyi M; Travis WD; Antonescu CR
Am J Surg Pathol; 2017 Jul; 41(7):980-988. PubMed ID: 28505004
[TBL] [Abstract][Full Text] [Related]
17. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma.
Christensen BC; Godleski JJ; Marsit CJ; Houseman EA; Lopez-Fagundo CY; Longacker JL; Bueno R; Sugarbaker DJ; Nelson HH; Kelsey KT
Carcinogenesis; 2008 Aug; 29(8):1555-9. PubMed ID: 18310086
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
[TBL] [Abstract][Full Text] [Related]
19. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
Ugurluer G; Chang K; Gamez ME; Arnett AL; Jayakrishnan R; Miller RC; Sio TT
Anticancer Res; 2016 May; 36(5):2331-8. PubMed ID: 27127140
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]